Business Daily from THE HINDU group of publications
Tuesday, Mar 13, 2007
ePaper
Business Daily from THE HINDU group of publications Tuesday, Mar 13, 2007 ePaper |
|
|
|
|
|
|
|
|
|
|
|
Home Page
-
Pharmaceuticals Corporate - Alliances & Joint Ventures Glenmark inks deal with Dyax for biologics Our Bureau
New path For discovery of therapeutic antibodies Dyax will get licence fees, employee payments Three leads expected to emerge from research
Mumbai March 12 After having built its pipeline of chemical products, Glenmark Pharmaceuticals Ltd has marked its entry into biologics. The Mumbai-based drugmaker has formalised a research agreement with Cambridge-based biopharmaceutical company Dyax Corp for the discovery of therapeutic antibodies. Biological products developed to cure illnesses are got from a living source. Glenmark has taken its first step to build a pipeline in this segment and expects the first lead from this research to go into clinical trials by 2009, Mr Glenn Saldanha, Managing Director and CEO, told Business Line. The deal has been executed through Glenmark's wholly owned Swiss subsidiary, Glenmark Pharmaceuticals SA. Dyax has a library of antibodies and they would identify therapeutic antibodies for three targets provided by Glenmark in the oncology and inflammation segments, he said. The leads that emerge from this research - three are expected - will return to Glenmark, which will further develop it to a certain threshold. The strategy with biologics will be a mirror image of what is being done on the new chemical entity (NCE) side, he added. On the NCE front, Glenmark has been developing products to a certain threshold, after which they are licensed out for further development to a partner with deep pockets. Glenmark has already done this with two of its prospective drug molecules in the asthma and diabetes segments. Since developing an NCE takes time, Glenmark has tried to speed up its strategy in developing new biological entities by using an existing library, Mr Saldanha said. Dyax will receive technology licence fees and full-time employee payments from Glenmark for the funded research. It will also receive clinical milestone payments and royalties on net sales that may result from Glenmark's development and commercialisation of antibodies from Dyax's libraries, a Glenmark note said. No financial details were divulged.
Related Stories: More Stories on : Pharmaceuticals | Alliances & Joint Ventures
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|
